Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?

Affiliations

¹ Department of Precision Medicine, Oncology, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
² CEINGE Biotecnologie Avanzate, 80145 Naples, Italy.

^# Contributed equally.

Editorial

Carminia Maria Della Corte et al. Explor Target Antitumor Ther. 2021.

. 2021;2(2):204-207.

doi: 10.37349/etat.2021.00041. Epub 2021 Apr 30.

¹ Department of Precision Medicine, Oncology, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
² CEINGE Biotecnologie Avanzate, 80145 Naples, Italy.

^# Contributed equally.

No abstract available

Conflict of interest statement

CMDC: Advisory Boards: MSD. FC: no conflict of interest to declare. FM: Advisory Boards: MSD, Lilly; Institutional Research Grants: AstraZeneca.

1. Castellanos EH, Horn L. Immunotherapy in lung cancer. Cancer Treat Res. 2016;170:203–23. 10.1007/978-3-319-40389-2_10 - DOI - PMC - PubMed
1. Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:171–210. 10.1093/annonc/mdy554 - DOI - PubMed
1. Della Corte CM, Gay CM, Byers LA. Beyond chemotherapy: emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era. Cancer. 2019;125:496–8. 10.1002/cncr.31863 - DOI - PMC - PubMed
1. Viscardi G, Di Natale D, Fasano M, Brambilla M, Lobefaro R, De Toma A., et al. Circulating biomarkers in malignant pleural mesothelioma. Explor Target Antitumor Ther. 2020;1:434–51. 10.37349/etat.2020.00028 - DOI - PMC - PubMed
1. Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646–61. 10.1158/2159-8290.CD-18-1020 - DOI - PMC - PubMed